Photobiomodulation (low-level light therapy) and dry eye disease

Dry eye disease is one of the most common, chief-complaints presenting in clinical practice, with a prevalence of up to 50%. Evaporative dry eye, as a result of meibomian gland dysfunction, is thought to be the biggest component factor. Treatments for meibomian gland dysfunction aim to restore tear film homoeostasis and include warm compress therapy, eyelid hygiene, in-office meibomian gland expression and lipid-containing, artificial tears. A recent introduction to the in-office treatments available for meibomian gland dysfunction has been low-level light therapy, also known as photobiomodulation. The technique involves applying red, or near infra-red, radiation using low-power light sources and is suggested to promote tissue repair, decrease inflammation, and relieve pain. This work aims to review the available literature on the efficacy and safety of photobiomodulation in meibomian gland dysfunction and dry eye disease, as well as what is currently known about its mechanism of action.

Automated summary

Dry eye disease is a common complaint in clinical practice, with evaporative dry eye often caused by meibomian gland dysfunction. Treatments for this dysfunction include warm compress therapy, eyelid hygiene, and artificial tears. Low-level light therapy, or photobiomodulation, is a new in-office treatment that may promote tissue repair and pain relief.